You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 23, 2024

CLINICAL TRIALS PROFILE FOR COL-PROBENECID


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Col-probenecid

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000670 ↗ Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 To evaluate the interaction of probenecid with zidovudine (AZT). Because AZT is eliminated quickly from the body, it must be taken frequently. A previous study showed that probenecid slowed the elimination of AZT without side effects, but that study lasted only 5 days. This study is to see whether this effect continues for 1 month and whether the continuation of probenecid and AZT is free of side effects over 1 month.
NCT00000706 ↗ Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 Part I studies the effect of quinine on how zidovudine (AZT) is used by the body and eliminated through the kidneys in HIV infected patients. Part II studies the effect of probenecid and quinine on the same aspects. Because AZT leaves the bloodstream quickly, patients must take the drug frequently to keep adequate amounts in their bodies. Probenecid and quinine may slow down the rate at which AZT leaves the body. Therefore, taking these drugs along with AZT may reduce the amount of AZT needed for treatment.
NCT00000799 ↗ HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol Completed Gilead Sciences N/A 1969-12-31 To evaluate short-term and long-term safety and efficacy of intravenous cidofovir (HPMPC) for treatment of small peripheral cytomegalovirus (CMV) retinitis lesions. To provide data on the relative safety and efficacy of 2 doses of HPMPC as maintenance regimens.
NCT00000799 ↗ HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 To evaluate short-term and long-term safety and efficacy of intravenous cidofovir (HPMPC) for treatment of small peripheral cytomegalovirus (CMV) retinitis lesions. To provide data on the relative safety and efficacy of 2 doses of HPMPC as maintenance regimens.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Col-probenecid

Condition Name

Condition Name for Col-probenecid
Intervention Trials
HIV Infections 10
Cytomegalovirus Retinitis 7
Healthy 6
Urinary Tract Infections 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Col-probenecid
Intervention Trials
HIV Infections 11
Communicable Diseases 8
Infections 7
Retinitis 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Col-probenecid

Trials by Country

Trials by Country for Col-probenecid
Location Trials
United States 195
Canada 10
Germany 6
South Africa 6
Poland 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Col-probenecid
Location Trials
California 16
Texas 13
New York 10
Ohio 10
Maryland 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Col-probenecid

Clinical Trial Phase

Clinical Trial Phase for Col-probenecid
Clinical Trial Phase Trials
Phase 4 6
Phase 3 10
Phase 2/Phase 3 3
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Col-probenecid
Clinical Trial Phase Trials
Completed 45
Not yet recruiting 11
Recruiting 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Col-probenecid

Sponsor Name

Sponsor Name for Col-probenecid
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 8
National Institutes of Health (NIH) 5
Iterum Therapeutics, International Limited 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Col-probenecid
Sponsor Trials
Industry 41
Other 34
NIH 21
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.